Abstract
In older adults who are developing Alzheimer-typical pathology but do not experience any symptoms—a condition termed “preclinical” Alzheimer’s disease—the individual prognostic value of current biomarkers is low. Only a minority of those who have positive findings on biomarkers in the cerebrospinal fluid or upon brain imaging experience cognitive decline within 3–5 years. On the other hand, the majority of people who have negative biomarker results remain cognitively intact. This may be expected in research settings where alternative causes of cognitive impairment are infrequent. The main reasons for the poor predictive performance of biomarkers in asymptomatic individuals are the dynamic nature of the assessments with abnormality evolving over time and the large interindividual variability of the threshold for clinical manifestation. We do not recommend biomarker assessment and disclosure of biomarker results to asymptomatic individuals outside of research protocols or clinical trials at this point in time. More needs to be learned about the interplay between biomarkers, risk factors, and protective factors. Also, studies are required with extended follow-up intervals on less selected participant groups to determine the long-term predictive potential of biomarkers in presymptomatic Alzheimer’s disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Vos SJB, Xiong C, Visser PJ et al (2013) Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort study. Lancet Neurol 12:957–965
Dubois B, Hampel H, Feldman HH et al (2016) Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement 12:292–323
Petersen RC (2011) Mild cognitive impairment. N Engl J Med 364:2227–2234
Ritchie K, Carrière I, Berr C et al (2016) The clinical picture of Alzheimer’s disease in the decade before diagnosis: clinical and biomarker trajectories. J Clin Psychiatry 77:e305–e311
Roberts JS, Dunn LB, Rabinovici GD (2013) Amyloid imaging, risk disclosure and Alzheimer’s disease: ethical and practical issues. Neurodegener Dis Manag 3:219–229
Witte MM, Foster NL, Fleisher AS et al (2015) Clinical use of amyloid-positron emission tomography neuroimaging: practical and bioethical considerations. Alzheimers Dement 1:358–367
Jack CR, Albert M, Knopman DS et al (2011) Introduction to revised criteria for the diagnosis of Alzheimer’s disease: national institute on aging and the Alzheimer association workgroups. Alzheimers Dement 7:257–262
Arlt S (2013) Non-Alzheimer’s disease–related memory impairment and dementia. Dialogues Clin Neurosci 15:465–473
Villemagne VL, Burnham S, Bourgeat P et al (2013) Amyloid beta deposition, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol 12:357–367
Han SD, Gruhl J, Beckett L et al (2012) Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer’s disease. Brain Imaging Behav 6:610–620
Jack CR, Knopman DS, Jagust WJ et al (2013) Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12:207–216
Sutphen CL, Jasielec MS, Shah AR et al (2015) Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA Neurol 72:1029–1042
Wirth M, Villeneuve S, Haase CM et al (2013) Association between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol 70:1512–1519
Knopman DS, Jack CR, Lundt ES et al (2015) Role of beta-amyloidosis and neurodegeneration in subsequent changes in mild cognitive impairment. JAMA Neurol 72:1475–1483
Alexopoulos P, Werle L, Roesler J et al (2016) Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease. Alzheimers Res Ther 8:51
Porteri C, Frisoni GB (2014) Biomarker-based diagnosis of mild cognitive impairment due to Alzheimer’s disease: how and what to tell. A kickstart to an ethical discussion. Front Aging Neurosci 6:41
Landau SM, Lu M, Joshi AD et al (2013) Comparing PET imaging and CSF measurements of A beta. Ann Neurol 74:826–836
Toledo JB, Weiner MW, Wolk DA et al (2014) Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathol Commun 2:26
Leuzy A, Carter SF, Chiotis K et al (2015) Concordance and diagnostic accuracy of 11C PIB PET and cerebrospinal fluid biomarkers in a sample of patients with mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis 45:1077–1088
Leuzy A, Chiotis K, Hasselbalch SG et al (2016) Pittsburgh compound B imaging and cerebrospinal fluid amyloid-beta in a multicentre European memory clinic study. Brain 139:2540–2553
Vos SJB, Gordon BA, Su Y et al (2016) NIAA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiol Aging 44:1–8
Valenzuela MJ (2008) Brain reserve and the prevention of dementia. Curr Opin Psychiatry 21:296–302
Murray AD, Staff RT, McNeil CJ et al (2011) The balance between cognitive reserve and brain imaging biomarkers of cerebrovascular and Alzheimer’s diseases. Brain 134:3687–3696
Almeida RP, Schultz SA, Austin BP et al (2015) Cognitive reserve modifies age-related alterations in CSF biomarkers of Alzheimer’s disease. JAMA Neurol 72:699–706
Doraiswamy PM, Sperling RA, Johnson K et al (2014) Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry 19:1044–1051
McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the national institute on aging and the Alzheimer’s association workgroup. Alzheimers Dement 7(3):263–269
Janelidze S, Zetterberg H, Mattsson N et al (2016) CSF Abeta 42/Abeta 40 and Abeta42/−abeta38 ratios: better diagnostic markers of Alzheimer’s disease. Ann Clin Transl Neurol 3:154–165
Counts SE, Ikonomovic MD, Mercao N et al (2017) Biomarkers for the early detection and progression of Alzheimer’s disease. Neurotherapeutics 14:35–53
Chételat G, La Joie R, Villain N et al (2013) Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer’s disease. NeuroImage Clin 2:356–365
Soldan A, Pettigrew C, Cai Q et al (2016) Hypothetical preclinical Alzheimer disease groups and longitudinal cognitive change. JAMA Neurol 73:698–705
Goldman JS (2012) New approaches to genetic counseling and testing for Alzheimer’s disease and frontotemporal degeneration. Curr Neurol Neurosci Rep 12:502–510
Hauser PS, Ryan RO (2013) Impact of apolipoprotein E on Alzheimer’s disease. Curr Alzheimer Res 10:809–817
Randall C, Mosconi L, de Leon M et al (2014) Cerebrospinal fluid biomarkers of Alzheimer’s disease in cognitively healthy elderly. Front Biosci 18:1150–1173
Fleisher AS, Chen K, Liu X et al (2013) Apolipoprotein E e4 effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging 34:1–12
Steenland K, Zhao L, Goldstein F et al (2014) Biomarkers for predicting cognitive decline in those with normal cognition. J Alzheimers Dis 40:587–594
Johnson KA, Minoshima S, Bohnen NI et al (2013) Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the society of nuclear medicine and molecular imaging, and the Alzheimer’s association. Alzheimers Dement 9:e-1–e-15
Morris JC, Roe CM, Grant EA et al (2009) PIB imaging predicts progression from cognitively normal to symptomatic Alzheimer’s disease. Arch Neurol 66:1469–1475
Villemagne VL, Pike KE, Chételat G et al (2011) Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 69:181–192
Harkins K, Sankar P, Sperling R et al (2015) Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. Alzheimers Res Ther 7:26
Rabinovici GD, Karlawish J, Knopman D et al (2016) Testing and disclosure related to amyloid imaging and Alzheimer’s disease: common questions and fact sheet summary. Alzheimers Dement 12:510–515
Rowe CC, Bourgeat P, Ellis KA et al (2013) Predicting Alzheimer disease with beta-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann Neurol 74:905–913
Howe E (2013) Clinical implications of the new diagnostic guidelines for dementia. Innov Clin Neurosci 10:32–38
Baum ML (2016) Patient requests for off-label bioprediction of dementia. Camb Q Healthc Ethics 25:686–690
Gordon M (2013) Identification of potential or preclinical cognitive impairment and the implications of sophisticated screening with biomarkers and cognitive testing: does it really matter? Biomed Res Int 2013:976130
Karlawish J (2011) Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease. Neurology 77:1487–1493
Kim SYH, Karlawish J, Berkman BE (2015) Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials. Neurology 84:1488–1494
Schicktanz S, Schweda M, Ballenger JF et al (2014) Before it is too late: professional responsibilities in late-onset Alzheimer’s research and pre-symptomatic prediction. Front Hum Neurosci 8:921
Caselli RJ, Langbaum J, Marchant GE et al (2014) Public perceptions of presymptomatic testing for Alzheimer’s disease. Mayo Clin Proc 89:1389–1396
Villemagne VL, Fodero-Tavoletti MT, Masters CL et al (2015) Tau imaging: early progress and future directions. Lancet Neurol 14:114–124
Tanzi RE (2012) The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2:a006296
Bemelmans SASA, Tromp K, Bunnik EM et al (2016) Psychological, behavioral and social effects of disclosing Alzheimer’s disease biomarkers to research participants: a systematic review. Alzheimers Res Ther 8:46
Lim YY, Maruff P, Getter C et al (2016) Disclosure of positron emission tomography amyloid imaging results: a preliminary study of safety and tolerability. Alzheimers Dement 12:454–458
Paulsen JS, Nance M, Kim JI et al (2013) A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases. Prog Neurobiol 110:2–28
Hooper M, Grill JD, Rodriguez-Agudelo Y et al (2013) The impact of the availability of prevention studies on the desire to undergo predictive testing in persons at-risk for autosomal dominant Alzheimer’s disease. Contemp Clin Trials 36:256–262
Steinbart EJ, Smith CO, Poorkay P et al (2001) Impact of DNA testing for early-onset familial Alzheimer disease and frontotemporal dementia. Arch Neurol 58:1828–1831
Cassidy MR, Roberts JS, Bird TD et al (2008) Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer’s disease. Alzheimers Dement 4:406–413
Goldman JS, Rademakers R, Huey ED et al (2011) An algorithm for genetic testing of frontotemporal lobar degeneration. Neurology 76:476–483
Molinuevo JL, Cami J, Carné S et al (2016) Ethical challenges in preclinical Alzheimer’s disease observational studies and trials: results of the Barcelona summit. Alzheimers Dement 12:614–622
Soldan A, Pettigrew C, Li S et al (2013) Relationship of cognitive reserve and CSF biomarkers to emergence of clinical symptoms in preclinical Alzheimer’s disease. Neurobiol Aging 34:2827–2834
Donovan NJ, Hsu DC, Dagley AS et al (2015) Depressive symptoms and biomarkers of Alzheimer’s disease in cognitively normal older adults. J Alzheimers Dis 46:63–73
Garrett MD, Valle R (2016) A methodological critique of the national institute of aging and Alzheimer’s association guidelines for Alzheimer’s disease, dementia, and mild cognitive impairments. Dementia 15:239–254
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Kurz, A.F., Lautenschlager, N.T. (2018). The Ethics of Biomarker-Based Preclinical Diagnosis of Alzheimer’s Disease. In: Perneczky, R. (eds) Biomarkers for Preclinical Alzheimer’s Disease. Neuromethods, vol 137. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7674-4_17
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7674-4_17
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7673-7
Online ISBN: 978-1-4939-7674-4
eBook Packages: Springer Protocols